Engineering of an ω-3 polyunsaturated fatty acid-containing nanoemulsion system for combination C6-ceramide and 17β-estradiol delivery and bioactivity in human vascular endothelial and smooth muscle cells

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 7, 2013, Pages 885-894

  Deshpande, Dipti ^a   Janero, David R ^a   Amiji, Mansoor ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Apoptosis; Arterial injury; Coronary disease; Endothelial dysfunction; Smooth muscle proliferation; Sphingolipid

Indexed keywords

ARTERIAL INJURIES; CORONARY DISEASE; ENDOTHELIAL DYSFUNCTION; SMOOTH MUSCLES; SPHINGOLIPIDS;

BIOACTIVITY; CELL DEATH; CELL PROLIFERATION; DISEASES; ENDOTHELIAL CELLS; POLYUNSATURATED FATTY ACIDS;

CERAMIDES;

CASPASE 3; CASPASE 7; CERAMIDE; ESTRADIOL; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; OIL; OMEGA 3 FATTY ACID; WATER;

APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; NANOEMULSION; NANOENGINEERING; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; ZETA POTENTIAL;

ANIMALIA;

APOPTOSIS; ARTERIAL INJURY; CORONARY DISEASE; ENDOTHELIAL DYSFUNCTION; SMOOTH MUSCLE PROLIFERATION; SPHINGOLIPID;

AORTA; APOPTOSIS; CASPASE 3; CASPASE 7; CELL PROLIFERATION; CERAMIDES; EMULSIONS; ENDOCYTOSIS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ESTRADIOL; FATTY ACIDS, OMEGA-3; HUMANS; INTRACELLULAR SPACE; MAP KINASE SIGNALING SYSTEM; MYOCYTES, SMOOTH MUSCLE; NANOPARTICLES; NANOTECHNOLOGY; PARTICLE SIZE; STATIC ELECTRICITY;

EID: 84884281682     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.02.007     Document Type: Article

References (40)

1. World Health Organization WHO FactSheet No 317, Cardiovascular diseases (CVDs) 2011.
2. Lloyd-Jones D., Adams R.J., Brown T.M., Carnethon M., Dai S., De Simone G., et al. Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 2010, 121:e46-e215.
3. Weintraub W. The pathophysiology and burden of restenosis. Am J Cardiol 2007, 100:3K-9K.
4. Perez J., Torres R.A., Rocic P., Cismowski M.J., Weber D.S., Darley-Usmar V.M., et al. PYK2 Signaling is required for PDGF-dependent vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol 2011, 301:C242-C251.
5. Vita J.A. Endothelial function. Circulation 2011, 124:e906-e912.
6. Deshpande D.D., Janero D.R., Amiji M. Therapeutic strategies for endothelial dysfunction. Expert Opin Biol Ther 2011, 11:1637-1654.
7. Kolodgie F.D., Farb A., Virmani R. Local delivery of ceramide for restenosis: Is there a future for lipid therapy?. Circ Res 2000, 87:264-267.
8. White C.R., Shelton J., Chen S.J., Darley-Usmar V., Allen L., Nabors C., et al. Estrogen restores endothelial cell function in an experimental model of vascular injury. Circulation 1997, 96:1624-1630.
9. Chandrasekar B., Nattel S., Tanguay J.F. Coronary artery endothelial protection after local delivery of 17β-estradiol during balloon angioplasty in a porcine model: a potential new pharmacologic approach to improve endothelial function. J Am Coll Cardiol 2001, 38:1570-1576.
10. Chandrasekar B., Sirois M.G., Geoffroy P., Lauzier D., Nattel S., Tanguay J.F. Local delivery of 17β-estradiol improves reendothelialization and decreases inflammation after coronary stenting in a porcine model. Thromb Haemost 2005, 94:1042-1047.
11. Han Y., Liang M., Kang J., Qi Y., Deng J., Xu K., et al. Estrogen-eluting stent implantation inhibits neointimal formation and extracellular signal-regulated kinase activation. Catheter Cardiovasc Interv 2007, 70:647-653.
12. Abizaid A., Chaves A.J., Leon M.B., Hauptmann K., Mehran R., Lansky A.J., et al. Randomized, double-blind, multicenter study of the polymer-based 17β-estradiol-eluting stent for treatment of native coronary artery lesions: six-month results of the ETHOS I trial. Catheter Cardiovasc Interv 2007, 70:654-660.
13. Airoldi F., Di Mario C., Ribichini F., Presbitero P., Sganzerla P., Ferrero V., et al. 17-β-estradiol eluting stent versus phosphorylcholine-coated stent for the treatment of native coronary artery disease. Am J Cardiol 2005, 96:664-667.
14. Ryu S.K., Mahmud E., Tsimikas S. Estrogen-eluting stents. J Cardiovasc Transl Res 2009, 2:240-244.
15. Lahiri S., Futerman A.H. The metabolism and function of sphingolipids and glycosphingolipids. Cell Mol Life Sci 2007, 64:2270-2284.
16. Westwick J.K., Bielawska A.E., Dbaibo G., Hannun Y.A., Brenner D.A. Ceramide activates the stress-activated protein kinases. J Biol Chem 1995, 270:22689-22692.
17. Coroneos E., Wang Y., Panuska J.R., Templeton D.J., Kester M. Sphingolipid metabolites differentially regulate extracellular signal-regulated kinase and stress-activated protein kinase cascades. Biochem J 1996, 316:13-17.
18. Deshpande D., Devalapally H., Amiji M. Enhancement in anti-proliferative effects of paclitaxel in aortic smooth muscle cells upon co-administration with ceramide using biodegradable polymeric nanoparticles. Pharm Res 2008, 25:1936-1947.
19. Geraldes P., Sirois M.G., Bernatchez P.N., Tanguay J.F. Estrogen regulation of endothelial and smooth muscle cell migration and proliferation: role of p38 and p42/44 mitogen-activated protein kinase. Arterioscler Thromb Vasc Biol 2002, 22:1585-1590.
20. Spyridopoulos I., Sullivan A.B., Kearney M., Isner J.M., Losordo D.W. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. Circulation 1997, 95:1505-1514.
21. Hammad S.M., Pierce J.S., Soodavar F., Smith K.J., Al Gadban M.M., Rembiesa B., et al. Blood sphingolipidomics in healthy humans: impact of sample collection methodology. J Lipid Res 2010, 51:3074-3087.
22. Rosner W., Hryb D.J., Kahn S.M., Nakhla A.M., Romas N.A. Interactions of sex hormone-binding globulin with target cells. Mol Cell Endocrinol 2010, 316:79-85.
23. Sturdee D.W. Current hormone replacement therapy: what are the shortcomings? Advances in delivery. Int J Clin Pract 1999, 53:468-472.
24. Ho K.K., O'Sullivan A.J., Wolthers T., Leung K.C. Metabolic effects of oestrogens: impact of the route of administration. Ann Endocrinol 2003, 64:170-177.
25. Gupta A.S. Nanomedicine approaches in vascular disease: a review. Nanomedicine 2011, 7:763-779.
26. McClements D.J., Decker E.A., Weiss J. Emulsion-based delivery systems for lipophilic bioactive components. J Food Sci 2007, 72:R109-R124.
27. Wang Q., Liang X., Wang L., Lu X., Huang J., Cao J., et al. Effect of omega-3 fatty acids supplementation on endothelial function: a meta-analysis of randomized controlled trials. Atherosclerosis 2012, 221:536-543.
28. Filion K.B., El Khoury F., Bielinski M., Schiller I., Dendukuri N., Brophy J.M. Omega-3 fatty acids in high-risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 2010, 10:24.
29. Ganta S., Devlapally H., Baguley B., Garg S., Amiji M. Microfluidic preparation of chlorambucil nanoemulsion formulations and evaluation of cytotoxicity and pro-apoptotic activity in cancer cells. J Biomed Nanotechnol 2008, 4:165-173.
30. Curcio A., Torella D., Indolfi C. Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ J 2011, 75:1287-1296.
31. Pan D., Williams T.A., Senpan A., Allen J.S., Scott M.J., Gaffney P.J., et al. Detecting vascular biosignatures with a colloidal, radio-opaque polymeric nanoparticle. J Am Chem Soc 2009, 131:15522-15527.
32. Prasad K. Flaxseed and cardiovascular health. J Cardiovasc Pharmacol 2009, 54:369-377.
33. Abeywardena M.Y., Patten G.S. Role of omega-3 longchain polyunsaturated fatty acids in reducing cardio-metabolic risk factors. Endocr Metab Immune Disord Drug Targets 2011, 11:232-246.
34. Fan Y.Y., Ramos K.S., Chapkin R.S. Dietary gamma-linolenic acid suppresses aortic smooth muscle cell proliferation and modifies atherosclerotic lesions in apolipoprotein E knockout mice. J Nutr 2001, 131:1675-1681.
35. Artwohl M., Lindenmair A., Roden M., Waldhausl W.K., Freudenthaler A., Klosner G., et al. Fatty acids induce apoptosis in human smooth muscle cells depending on chain length, saturation, and duration of exposure. Atherosclerosis 2009, 202:351-362.
36. Artwohl M., Lindenmair A., Sexl V., Maier C., Rainer G., Freudenthaler A., et al. Different mechanisms of saturated versus polyunsaturated FFA-induced apoptosis in human endothelial cells. J Lipid Res 2008, 49:2627-2640.
37. Cui P.H., Petrovic N., Murray M. The omega-3 epoxide of eicosapentaenoic acid inhibits endothelial cell proliferation by p38 MAP kinase activation and cyclin D1/CDK4 down-regulation. Br J Pharmacol 2011, 162:1143-1155.
38. Shyu K.G. Cellular and molecular effects of mechanical stretch on vascular cells and cardiac myocytes. Clin Sci 2009, 116:377-389.
39. Ono K., Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000, 12:1-13.
40. Lamkanfi M., Kanneganti T.D. Caspase-7: a protease involved in apoptosis and inflammation. Int J Biochem Cell Biol 2010, 42:21-24.